logo-loader
viewAstraZeneca

AstraZeneca pauses Oxford coronavirus vaccine trial after adverse effect

The pharma giant said it is standard routine to allow review of safety data to ensure the integrity of the trials

AstraZeneca - AstraZeneca pauses Oxford COVID-19 vaccine trial after adverse effect

AstraZeneca PLC (LON:AZN) said it has paused human trials of the coronavirus (COVID-19) vaccine under development by Oxford University after a participant in the UK registered adverse effects.

The pharma giant said it is standard routine to allow a review of safety data to ensure the integrity of the trials.

READ: The runners in the COVID-19 vaccine race

“In large trials illnesses will happen by chance but must be independently reviewed to check this carefully,” a spokesperson for the drug company told STAT News.

“We are working to expedite the review of the single event to minimise any potential impact on the trial timeline.”

The late-stage clinical studies were conducted on 30,000 people across the US, South Africa, England, Russia and Brazil.

Oxford’s Professor Andrew Pollard said in August data could be put before regulators as early as this year but ensuring safety and efficacy is paramount.

Analysts at Liberum noted "there is clearly a risk the vaccine fails at this hurdle", while if the adverse effect does not relate to the candidate "the study could be up and running again within weeks".

Astra shares shed 1% to 8,284p on Wednesday at the opening bell.

--Adds analyst comment, shares--

Quick facts: AstraZeneca

Price: 8746 GBX

LSE:AZN
Market: LSE
Market Cap: £114.77 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: FTSE fragile Friday despite UK shoppers continuing to splurge...

Good morning, it’s a fragile Friday for the FTSE despite signs of some retail therapy as British retail sales continued to increase for the fourth consecutive month, boosted by spending on household goods and DIY, according to the ONS.  J Sainsbury PLC (LON:SBRY) is up after a...

2 days, 3 hours ago

2 min read